Retraction notice to "S14G-humanin Ameliorates Aβ 25-35-induced Behavioral Deficits by Reducing Neuroinflammatory Responses and Apoptosis in Mice" [Neuropeptides 42/5-6 (2008) 557-567] doi: 10.1016/j.npep.2008.08.004.;S14G-Humanin ameliorates Aβ25-35-induced behavioral deficits by reducing neuroinflammatory responses and apoptosis in mice

Neuropeptides

Volumn 42, Issue 5-6, 2008, Pages 557-567

  Miao, Jianting ^a   Zhang, Wei ^a   Yin, Rong ^a   Liu, Rui ^a   Su, Changjun ^a   Lei, Gesheng ^a   Li, Zhuyi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Apoptosis; Behavioral deficits; Beta amyloid protein; Neuroinflammation; S14G Humanin

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CHOLINERGIC RECEPTOR BLOCKING AGENT; HUMANIN; INTERLEUKIN 6; PROTEIN S14G; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; BEHAVIOR DISORDER; CONTROLLED STUDY; DRUG ACTIVITY; ENCEPHALITIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; MICROGLIA; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

MUS;

EID: 56349147722     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2016.03.001     Document Type: Erratum

References (51)

1. Aisen P.S. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 1 (2002) 279-284
2. Bradl M., and Hohlfeld R. Molecular pathogenesis of neuroinflammation. J. Neurol. Neurosurg. Psychiatr. 74 (2003) 1364-1370
3. Cheng G., Whitehead S.N., Hachinski V., and Cechetto D.F. Effects of pyrrolidine dithiocarbamate on beta-amyloid (25-35)-induced inflammatory responses and memory deficits in the rat. Neurobiol. Dis. 23 (2006) 140-151
4. Combs C.K., Karlo J.C., Kao S.C., and Landreth G.E. Beta-amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 21 (2001) 1179-1188
5. Dörr J., Roth K., Zurbuchen U., Deisz R., Bechmann I., Lehmann T.N., Meier S., Nitsch R., and Zipp F. Tumor-necrosis-factor-related apoptosis-inducing-ligand (TRAIL)-mediated death of neurons in living human brain tissue is inhibited by flupirtine-maleate. J. Neuroimmunol. 167 (2005) 204-209
6. Dudal S., Krzywkowski P., Paquette J., Morissette C., Lacombe D., Tremblay P., and Gervais F. Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol. Aging 25 (2004) 861-871
7. Eikelenboom P., Veerhuis R., Familian A., Hoozemans J.J., van Gool W.A., and Rozemuller A.J. Neuroinflammation in plaque and vascular beta-amyloid disorders: clinical and therapeutic implications. Neurodegener. Dis. 5 (2008) 190-193
8. Eikelenboom P., Veerhuis R., Scheper W., Rozemuller A.J., van Gool W.A., and Hoozemans J.J. The significance of neuroinflammation in understanding Alzheimer's disease. J. Neural Trans. 113 (2006) 1685-1695
9. Etminan M., Gill S., and Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327 (2003) 128
10. Fan R., Xu F., Previti M.L., Davis J., Grande A.M., Robinson J.K., and Van Nostrand W.E. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J. Neurosci. 27 (2007) 3057-3063
11. Golde T.E. Alzheimer disease therapy: can the amyloid cascade be halted?. J. Clin. Invest. 111 (2003) 11-18
12. Grace E.A., Rabiner C.A., and Busciglio J. Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease. Neuroscience 114 (2002) 265-273
13. Guo B., Zhai D., Cabezas E., Welsh K., Nouraini S., Satterthwait A.C., and Reed J.C. Humanin peptide suppresses apoptosis by interfering with Bax activation. Nature 423 (2003) 456-461
14. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
15. Hashimoto Y., Ito Y., Niikura T., Shao Z., Hata M., Oyama F., and Nishimoto I. Mechanisms of neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein. Biochem. Biophys. Res. Commun. 283 (2001) 460-468
16. Hashimoto Y., Niikura T., Ito Y., Sudo H., Hata M., Arakawa E., Abe Y., Kita Y., and Nishimoto I. Detailed characterization of neuroprotection by a rescue factor humanin against various Alzheimer's disease-relevant insults. J. Neurosci. 21 (2001) 9235-9245
17. Hashimoto Y., Niikura T., Tajima H., Yasukawa T., Sudo H., Ito Y., Kita Y., Kawasumi M., Kouyama K., Doyu M., Sobue G., Koide T., Tsuji S., Lang J., Kurokawa K., and Nishimoto I. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proc. Natl. Acad. Sci. USA 98 (2001) 6336-6341
18. Ikonen M., Liu B., Hashimoto Y., Ma L., Lee K.W., Niikura T., Nishimoto I., and Cohen P. Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc. Natl. Acad. Sci. USA 100 (2003) 13,042-13,047
19. Johnstone M., Gearing A.J., and Miller K.M. A central role for astrocytes in the inflammatory response to beta-amyloid; chemokines, cytokines and reactive oxygen species are produced. J. Neuroimmunol. 93 (1999) 182-193
20. Krejcova G., Patocka J., and Slaninova J. Effect of humanin analogues on experimentally induced impairment of spatial memory in rats. J. Pept. Sci. 10 (2004) 636-639
21. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., and Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20 (2000) 5709-5714
22. Lockhart B.P., Benicourt C., Junien J.L., and Privat A. Inhibitors of free radical formation fail to attenuate direct b-amyloid25-35 peptide-mediated neurotoxicity in rat hippocampal cultures. J. Neurosci. Res. 39 (1994) 494-505
23. Luciano F., Zhai D., Zhu X., Bailly-Maitre B., Ricci J.E., Satterthwait A.C., and Reed J.C. Cytoprotective peptide humanin binds and inhibits proapoptotic Bcl-2/Bax family protein BimEL. J. Biol. Chem. 280 (2005) 15,825-15,835
24. Luterman J.D., Haroutunian V., Yemul S., Ho L., Purohit D., Aisen P.S., Mohs R., and Pasinetti G.M. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch. Neurol. 57 (2000) 1153-1160
25. Mamiya T., and Ukai M. [Gly(14)]-humanin improved the learning and memory impairment induced by scopolamine in vivo. Br. J. Pharmacol. 134 (2001) 1597-1599
26. Maurice T., Lockhart B.P., and Privat A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res. 706 (1996) 181-193
27. McGeer P.L., and McGeer E.G. Inflammation and the degenerative diseases of aging. Ann. NY Acad. Sci. 1035 (2004) 104-116
28. Meda L., Baron P., Prat E., Scarpini E., Scarlato G., Cassatella M.A., and Rossi F. Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid [25-35]. J. Neuroimmunol. 93 (1999) 45-52
29. Mehlhorn G., Hollborn M., and Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int. J. Dev. Neurosci. 18 (2000) 423-431
30. Miao J., Xu F., Davis J., Otte-Holler I., Verbeek M.M., and Van Nostrand W.E. Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. Am. J. Pathol. 167 (2005) 505-515
31. Mrak R.E., and Griffin W.S. The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease. Neurobiol. Aging 22 (2001) 915-922
32. Niikura T., Chiba T., Aiso S., Matsuoka M., and Nishimoto I. Humanin: after the discovery. Mol. Neurobiol. 30 (2004) 327-340
33. Nishimoto I., Matsuoka M., and Niikura T. Unravelling the role of Humanin. Trends Mol. Med. 10 (2004) 102-105
34. Parachikova A., Agadjanyan M.G., Cribbs D.H., Blurton-Jones M., Perreau V., Rogers J., Beach T.G., and Cotman C.W. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol. Aging 28 (2007) 1821-1833
35. Parachikova A., Nichol K.E., and Cotman C.W. Short-term exercise in aged Tg2576 mice alters neuroinflammation and improves cognition. Neurobiol. Dis. 30 (2008) 121-129
36. Pasinetti G.M. Cyclooxygenase and Alzheimer's disease: implications for preventive initiatives to slow the progression of clinical dementia. Arch. Gerontol. Geriatr. 33 (2001) 13-28
37. Pike C.J., Burdick D., Walencewicz A.J., Glabe C.G., and Cotman C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13 (1993) 1676-1687
38. Rojo L.E., Fernández J.A., Maccioni A.A., Jimenez J.M., and Maccioni R.B. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch. Med. Res. 39 (2008) 1-16
39. Rozemuller A.J., van Gool W.A., and Eikelenboom P. The neuroinflammatory response in plaques and amyloid angiopathy in Alzheimer's disease: therapeutic implications. Curr. Drug Targets CNS Neurol. Disord. 4 (2005) 223-233
40. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 6 (1991) 487-498
41. Stadelmann C., Deckwerth T.L., Srinivasan A., Bancher C., Bruck W., Jellinger K., and Lassmann H. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am. J. Pathol. 155 (1999) 1459-1466
42. Stepanichev M.Y., Zdobnova I.M., Zarubenko I.I., Moiseeva Y.V., Lazareva N.A., Onufriev M.V., and Gulyaeva N.V. Amyloid-beta(25-35)-induced memory impairments correlate with cell loss in rat hippocampus. Physiol. Behav. 80 (2004) 647-655
43. Storozheva Z.I., Proshin A.T., Sherstnev V.V., Storozhevykh T.P., Senilova Y.E., Persiyantseva N.A., Pinelis V.G., Semenova N.A., Zakharova E.I., and Pomytkin I.A. Dicholine salt of succinic acid, a neuronal insulin sensitizer, ameliorates cognitive deficits in rodent models of normal aging, chronic cerebral hypoperfusion, and beta-amyloid peptide-(25-35)-induced amnesia. BMC Pharmacol. 8 (2008) 1
44. Tajima H., Kawasumi M., Chiba T., Yamada M., Yamashita K., Nawa M., Kita Y., Kouyama K., Aiso S., Matsuoka M., Niikura T., and Nishimoto I. A humanin derivative, S14G-HN, prevents amyloid-beta-induced memory impairment in mice. J. Neurosci. Res. 79 (2005) 714-723
45. Townsend K.P., and Pratico D. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB J. 19 (2005) 1592-1601
46. Tsunekawa H., Noda Y., Mouri A., Yoneda F., and Nabeshima T. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). Behav. Brain Res. 190 (2008) 224-232
47. Walsh D.M., and Selkoe D.J. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44 (2004) 181-193
48. Wang D., Li H., Yuan H., Zheng M., Bai C., Chen L., and Pei X. Humanin delays apoptosis in K562 cells by downregulation of P38 MAP kinase. Apoptosis 10 (2005) 963-971
49. Wang D., Noda Y., Zhou Y., Mouri A., Mizoguchi H., Nitta A., Chen W., and Nabeshima T. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in beta amyloid25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 32 (2007) 1261-1271
50. Xu F., Grande A.M., Robinson J.K., Previti M.L., Vasek M., Davis J., and Van Nostrand W.E. Early-onset subicular microvascular amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precursor transgenic mice. Neuroscience 146 (2007) 98-107
51. Yamada K., and Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol. Ther. 88 (2000) 93-113